A Study of LY3885125 in Participants With Dyslipidemia or Non-Alcoholic Fatty Liver Disease (NAFLD)
Conditions: Dyslipidemias; Non-Alcoholic Fatty Liver Disease Interventions: Drug: LY3885125; Drug: Placebo Sponsor: Eli Lilly and Company Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Alcoholism | Fatty Liver Disease (FLD) | Liver | Liver Disease | Non-alcoholic Fatty Liver Diseases (NAFLD) | Research | Study | Urology & Nephrology